Literature DB >> 22849496

Safety and efficacy of large balloon sphincteroplasty in a third care hospital.

Eduardo Martín-Arranz1, Rafael Rey-Sanz, María Dolores Martín-Arranz, Francisco Gea-Rodríguez, Pedro Mora-Sanz, José María Segura-Cabral.   

Abstract

BACKGROUND AND AIMS: large balloon sphincteroplasty (LBS) associated with sphincterotomy (ES) has gained acceptance as a useful tool in extracting difficult bile duct stones. Our purpose was to evaluate the efficacy and safety of LBS with balloons > or = 10 mm in clinical practice setting. PATIENTS AND METHODS: unicentre prospective study in a tertiary care hospital. All patients who underwent LBS associated with ES between July 2007 and March 2011 were included prospectively in a database recording clinical aspects, procedure data, outcome and complications.Success is the main outcome defined as complete stone removal documented by absence of any filling defect during a final occlusion cholangiogram and absence of clinical or radiological findings after the ERCP consistent with remaining stones. Complications as pancreatitis, cholangitis, post-ERCP bleeding, perforation and others were also measured.
RESULTS: one hundred twenty procedures were made in 109 patients with balloons ranging from 10 to 20 mm. Success rate was 91% in the first attempt and 96.7% after two procedures. Mechanical lithotripsy was only needed in one case (0.8%). Complication rate was 4.2% due to five cases of post-ERCP bleeding in high risk patients.
CONCLUSION: large balloon sphincteroplasty associated to sphincterotomy in clinical practice is a very effective and safe technique.

Entities:  

Mesh:

Year:  2012        PMID: 22849496     DOI: 10.4321/s1130-01082012000700004

Source DB:  PubMed          Journal:  Rev Esp Enferm Dig        ISSN: 1130-0108            Impact factor:   2.086


  1 in total

Review 1.  Endoscopic papillary large balloon dilation for the removal of bile duct stones.

Authors:  Jin Hong Kim; Min Jae Yang; Jae Chul Hwang; Byung Moo Yoo
Journal:  World J Gastroenterol       Date:  2013-12-14       Impact factor: 5.742

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.